Skip to content

Study · Not a test of the peptide alone · 2009

1 result

Substitution of arginine with proline and proline derivatives in melanocyte-stimulating hormones leads to selectivity for human melanocortin 4 receptor.

Qu H, Cai M, Mayorov AV, Grieco P, Zingsheim M, Trivedi D, Hruby VJ

Journal of medicinal chemistry1 Jun 2009Cited by 11 (Europe PMC)

PMID19473029 (opens in a new tab)PMCIDPMC2775485 (opens in a new tab)DOI10.1021/jm801300c (opens in a new tab)PepBankPUB-19473029
Source linkPubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan II.

  1. 01LabNot a test of Melanotan II aloneIn vitro (cells)Activity measurement

    Analogues 1 and 2 were insurmountable inhibitors of MTII agonist activity at the human MC4R; MTII served as the challenge agonist.

    In plain wordsIn lab tests, two new analogues blocked the action of MTII at the human MC4R receptor.

    Peptide
    Melanotan II
    Outcome
    DecreaseInhibition of MTII agonist activity at hMC4R by analogues 1 and 2
    Study

    humann: not reported in source

    second messenger assays at human MC4R
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    Second messenger studies have demonstrated that analogues 1 and 2 are insurmountable inhibitors of MTII agonist activity at the hMC4R.

    In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan II.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.